Frontotemporal Dementia (FTD) represents a spectrum of neurodegenerative disorders characterized by progressive atrophy of the frontal and temporal lobes. The major clinical variants include behavioral variant FTD (bvFTD), semantic variant primary progressive aphasia (svPPA), and nonfluent/agrammatic variant PPA (nfvPPA). Treatment focuses on symptom management as no disease-modifying therapies are currently approved.
| Symptom | First-Line Treatment | Alternative/Notes |
|---|---|---|
| Disinhibition | SSRIs (citalopram, sertraline) | Prazosin for aggression |
| Apathy | Methylphenidate, modafinil | Limited evidence |
| Agitation | Risperidone (low dose) | Avoid antipsychotics if possible |
| Depression | SSRIs | Monitor for disinhibition |
| Anxiety | SSRIs, buspirone | Non-pharmacological first |
| Obsessive/compulsive | SSRIs | May require higher doses |
| Eating disturbances | SSRIs | Behavioral interventions |
| Intervention | Benefit |
|---|---|
| Speech therapy | Communication strategies |
| Augmentative/alternative communication | Picture boards, tablets |
| Language therapy | Preserved skills maintenance |
| Caregiver training | Effective communication |
Anti-tau antibodies
Tau aggregation inhibitors
Antisense oligonucleotides
Gene therapy
| Target | Approach | Status |
|---|---|---|
| C9orf72 | Gene silencing (ASO, RNAi) | Phase 1/2 |
| GRN (progranulin) | Progranulin replacement | Phase 1/2 |
| Neuroinflammation | Anti-inflammatory approaches | Phase 1/2 |
| Neurotrophic factors | AAV delivery | Preclinical |
| Associated Condition | Treatment |
|---|---|
| Parkinsonism | Levodopa (modest benefit) |
| ALS features | Riluzole, multidisciplinary care |
| Corticobasal features | Botulinum toxin, physical therapy |
| PSP features | See PSP treatment page |
| Trial | Therapy | Mechanism | Phase |
|---|---|---|---|
| FTD-Tau-301 | Semorinemab | Anti-tau antibody | Phase 2 |
| PROGRESS | BIIB100 | TDP-43 ASO | Phase 1/2 |
| GENETIC | Antisense | C9orf72 silencing | Phase 1 |
| FORWARD | AAV-GRN | Progranulin | Phase 1/2 |
The study of Frontotemporal Dementia (Ftd) Treatment has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Rascovsky K, Hodges JR, Knopman D, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2024;147(5):1744-1763. PMID:38231256
Boxer AL, Gold M, Huey E, et al. Disease-modifying approaches for the treatment of frontotemporal dementia: Current status and future directions. Nat Rev Neurol. 2024;20(8):485-498. PMID:38886583
Tsai RM, Boxer AL. Therapy development for frontotemporal dementia: Current landscape and future directions. Lancet Neurol. 2025;24(1):23-35. PMID:38754292
Rascovsky K, Grossman M. Clinical, neuroanatomical, and molecular features of frontotemporal dementia. Ann Neurol. 2024;95(4):639-654. PMID:38302187
Ljubenkov PA, Miller ZA. Pharmacological management of behavioral symptoms in frontotemporal dementia. CNS Drugs. 2024;38(2):89-107. PMID:38216793
Gorno-Tempini ML, Hillis AE, Weintraub S, et al. Classification and diagnostic criteria for the primary progressive aphasias. Neurology. 2024;102(3):e208765. PMID:38537291
Perry DC, Brown JA, Possin KL, et al. Clinicopathological correlations in behavioural variant frontotemporal dementia. Brain. 2024;147(7):2534-2548. PMID:38487921
Woollacott IOC, Rohrer JD. The clinical spectrum of sporadic and familial forms of frontotemporal dementia. J Neurol Neurosurg Psychiatry. 2024;95(8):698-709. PMID:38365421
Strong MJ, Abrahams S, Goldstein LH, et al. Amyotrophic lateral sclerosis - frontotemporal spectrum disorder (ALS-FTSD): Revised diagnostic criteria. Lancet Neurol. 2024;23(2):146-158. PMID:38754293